
Feature|Articles|October 8, 2026
Fast Is Not the Same as Trustworthy: The Data Standing Behind an Effective AI Answer
Author(s)Kapil Chaddha, Sarah Bickley
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Advertisement
Advertisement
Pharmaceutical companies are not short on market data. Most hold more than their teams can practically use, including sales trends, promotional spend and effort, health care professional (HCP) sentiment, competitive intelligence, pipeline intelligence, loss-of-exclusivity timelines and forecasts.1 Over the past two years, the industry conversation has focused on what artificial intelligence (AI) could do with all that data. While that question has largely been settled, a more difficult one has emerged: Can the answers be trusted?
Related to this article

A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.

The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.

How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.

Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.

ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.

How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
Advertisement
Advertisement


